Smith Group Asset Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Smith Group Asset Management’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-8,035	Closed	-$489K	–	499
2015 Q3	$489K	Sell	8,035 -2	-0%	-$144	0.02%	194
2015 Q2	$627K	Buy	8,037 +286	+4%	+$24K	0.02%	185
2015 Q1	$526K	Sell	7,751 -588	-7%	-$50.4K	0.02%	196
2014 Q4	$773K	Sell	8,339 -830	-9%	-$85.8K	0.03%	190
2014 Q3	$966K	Buy	+9,169	New	+$1.28M	0.04%	177

Other funds holding MDGL

Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Smith Group Asset Management's MDGL Position: Q4 2015 in Review

Smith Group Asset Management sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2015, closing a stake of 8,035 shares — an estimated $489K sold.

Smith Group Asset Management first reported a position in MDGL in Q3 2014 and held it in 5 quarters. The position peaked at $966K in Q3 2014. 75 funds tracked by Wall St. Rank hold MDGL as of Q4 2015.

Smith Group Asset Management reported no remaining Madrigal Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
Smith Group Asset Management sold 8,035 Madrigal Pharmaceuticals shares in Q4 2015, an estimated $489K.
Smith Group Asset Management first reported a position in Madrigal Pharmaceuticals in Q3 2014 and held it in 5 quarters.
Smith Group Asset Management's Madrigal Pharmaceuticals position peaked at $966K in Q3 2014.
75 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2015.

Based on Smith Group Asset Management's 13F filing for Q4 2015, filed 3 Feb 2016.